VIVEK SUBBIAH to Neovascularization, Pathologic
This is a "connection" page, showing publications VIVEK SUBBIAH has written about Neovascularization, Pathologic.
Connection Strength
0.168
-
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806.
Score: 0.091
-
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-1018.
Score: 0.078